Deltex Medical Group plc AGM 28 April 2011

1. Deltex Medical Group plcAGM 28 April 2011 Ewan Phillips

2. Introduction World leader in ODM Intervene – fluid during surgery Monitor – cardiac output in critical care Simple – to learn, to use & very safe Evidence – robust: clinical & economic Implementation Bottom-up – hospital level by procedure Top-down – system level standard of care

3. Platform for growth • Sales growing • Fastest growth in surgery in UK & US • High margins • 74% overall • >80% in direct markets • Stable cost base • Cash positive in second half

4. Financial Highlights - Cash

5. NICE guidance • Important validation • Positive recommendation for surgery • Reduce post-operative complications • Reduce cost by circa £1,100 per patient • Major and high risk surgery • Over 800,000 NHS patients a year • “Dominant” technology • Still need change in practice and NHS cash

6. UK growth strategy • £20 billion savings target • Innovative Technologies Adoption Procurement Programme • National Technology Adoption Centre support • Enhanced recovery – national roll-out • NICE evaluation pathway • Issued 30 March • Product specific • Extra income for NHS hospitals under CQUIN • Oesophageal Doppler specific • Enhanced recovery

7. International growth strategy • US Strategy • Demonstration ‘stories’ from existing accounts • Stand-alone improvement & enhanced recovery • Targeting hospital groupings with ‘quality’ agendas • Quality indicator for surgery • International Strategy • Build on Paris tender in France • Support Spanish projects to conclusions • ‘Exporting’ NICE, NTAC, CQUIN, enhanced recovery

8. Summary • ODM solves a major clinical problem • ODM implementable: • Stand-alone change in practice • Enhanced recovery surgical programmes • Evidence key to system wide adoption • NICE guidance is important validation • Growth rates encouraging • Potential for considerable acceleration